Innovations in Bladder Cancer: A New Hope for Patients
In this CURE Connections® program, Dr Philippa Cheetham reviews the protocol for diagnosing and treating bladder cancer with Dr Elizabeth Plimack and her partnering registered nurse, Jeanne Marie Wheatley. Patient Michael Molnar and his wife and caregiver, Sandy, join the program to discuss Michael’s journey through treatment. Additionally, advocate Dr Stephanie Chisolm highlights services and resources, provided through the Bladder Cancer Advocacy Network, that help support patients and loved ones navigating through a similar diagnosis.
▼ Episode 1 The Warning Signs of Bladder Cancer
Dr Philippa Cheetham and Dr Elizabeth Plimack discuss risk factors and symptoms commonly associated with bladder cancer. Michael Molnar and his wife, Sandy, reflect on urinary symptoms that led Michael to consult with a urologist.
Dr Elizabeth Plimack explains how depth of muscle invasion plays a role bladder cancer treatment decisions. Michael and Sandy Molnar recall what it was like to receive the news that Michael had been diagnosed with an early-stage bladder cancer.
After failing two courses of BCG therapy, Michael and Sandy Molnar explain what it was like to make the decision for Michael to undergo bladder cancer surgery. Dr Elizabeth Plimack and Dr Philippa Cheetham discuss ways to connect with the right care team and become educated on options before undergoing treatment.
Michael and Sandy Molnar reflect on what it was like having Michael’s plans for surgery and reconstruction change after the surgeon found more extensive disease than was expected. Dr Elizabeth Plimack discusses the appropriateness of post-surgical treatment with chemotherapy.
► Episode 7 Chemotherapy for Metastatic Bladder Cancer
Michael Molnar discusses the side effects he experienced throughout chemotherapy and highlights the support that he received to help him cope. Dr Elizabeth Plimack explains how oncologists monitor and manage patient side effects and measure treatment response.
Dr Elizabeth Plimack and Dr Philippa Cheetham discuss the potential of treating bladder cancer patients with newer immunotherapy agents, and remark on the accessibility and affordability of these treatment options.
Dr Stephanie Chisolm and Dr Elizabeth Plimack recognize challenges surrounding public awareness of bladder cancer risk factors, such as smoking, and reinforce the role of research in improving outcomes for bladder cancer patients.